Is PLYX or PRAX more undervalued in 2026?

CirclFi compares Polaryx Therapeutics, Inc. (PLYX) and Praxis Precision Medicines, Inc (PRAX) using 13 institutional-grade valuation models. PLYX has a Quality of Company score of 4.3/10 while PRAX scores 5.6/10.

Which is a better buy — PLYX or PRAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLYX and PRAX valuations compare?

PLYX at $3.27 and PRAX at $349.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLYX vs PRAX Valuation Comparison 2026 — Intrinsic Value Analysis

PLYX

Pharmaceutical Preparations

Polaryx Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

—

Price

$3.27

Last close

Models

8/13

Active

PRAX

Pharmaceutical Preparations

Praxis Precision Medicines, Inc

Quality

5.6

out of 10

Value Trap

SAFE

Price

$349.97

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	PLYX Fair Value	PLYX Upside	PRAX Fair Value	PRAX Upside
Bayesian DCF	Intrinsic	$0.95	-70.8%	$111.23	-68.2%
Earnings Power Value	Intrinsic	—	—	$151.65	-56.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.19	-94.2%	$45.59	-87.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLYX vs PRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLYX vs PRAX — Which Stock Is More Undervalued?

PRAX scores higher with a 5.6/10 quality rating vs PLYX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Polaryx Therapeutics, Inc. (PLYX) and Praxis Precision Medicines, Inc (PRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLYX currently trades at $3.27 with a QOC of 4.3/10, while PRAX trades at $349.97 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).